The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.
Access to MS Care in Underserved and Diverse Populations: Marisa McGinley, DO
February 26th 2023The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke at the 2023 ACTRIMS Forum about disparities in care access for patients with MS. [WATCH TIME: 5 minutes]
Ocrelizumab and Rituximab Demonstrate Similar Safety, Efficacy in Treatment of Multiple Sclerosis
February 25th 2023Treatment with either rituximab and ocrelizumab, 2 FDA-approved therapies that target CD20, resulted in similar odds of experiencing a clinical disease activity in both unadjusted and adjusted analyses.
Gauging MS Disease Activity Through Octave’s MSDA Test: Taylor Gonyou, DO
February 24th 2023The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]
Glatiramer Acetate Depot Injection Shows T1 and T2 Lesion Reduction in Relapsing MS
February 24th 2023Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.
Inside Look at Themes, Sessions at ACTRIMS 2023 Forum: Daniel Ontaneda, MD
February 22nd 2023The program committee vice-chair of ACTRIMS provided perspective on the upcoming forum, including the notable sessions, themes, and presentations the clinical community should be aware of. [WATCH TIME: 7 minutes]
Where Tolebrutinib and Other BTK Inhibitors Fit in the MS Treatment Landscape: Jiwon Oh, MD, PhD
March 15th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]
Overview of Tolebrutinib’s Positive 18-Month Data in Relapsing MS: Jiwon Oh, MD, PhD
March 10th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]
NeuroVoices: Jiwon Oh, MD, PhD, on Radiologically Isolated Syndrome as a Precursor to MS
March 9th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.
The Need for Guidelines on the Management of Radiologically Isolated Syndrome: Jiwon Oh, MD, PhD
March 8th 2022The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.